UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No.)*

 

VIRIDIAN THERAPEUTICS, INC.

(Name of Issuer)

 

Common Stock, par value $0.01 per share

(Title of Class of Securities)

 

92790C104

(CUSIP Number)

 

May 9, 2022

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP No. 92790C104 SCHEDULE 13G Page 2 of 7

 

1

NAME OF REPORTING PERSONS

 

Commodore Capital LP

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐

(b) ☐

3

SEC USE ONLY

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware, USA

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

1,371,339*

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

1,371,339*

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

1,371,339*

10

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

5.0%*

12

TYPE OF REPORTING PERSON

 

IA

 

*See Item 4 for additional information.

 

 

 

 

CUSIP No. 92790C104 SCHEDULE 13G Page 3 of 7

 

1

NAME OF REPORTING PERSONS

 

Commodore Capital Master LP

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ☐

(b) ☐

3

SEC USE ONLY

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Cayman Islands

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5

SOLE VOTING POWER

 

0

6

SHARED VOTING POWER

 

1,371,339*

7

SOLE DISPOSITIVE POWER

 

0

8

SHARED DISPOSITIVE POWER

 

1,371,339*

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

1,371,339*

10

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

5.0%*

12

TYPE OF REPORTING PERSON

 

OO

 

*See Item 4 for additional information.

 

 

 

 

CUSIP No. 92790C104  SCHEDULE 13G Page 4 of 7

 

Item 1. (a) Name of Issuer

 

Viridian Therapeutics, Inc. (the “Issuer”)

 

Item 1. (b) Address of Issuer’s Principal Executive Offices

 

221 Crescent Street, Suite 401, Waltham, MA 02453

 

Item 2. (a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship:

 

This report on Schedule 13G is being filed by Commodore Capital LP, a Delaware limited partnership (the “Firm”) and Commodore Capital Master LP, a Cayman Islands exempted limited partnership (“Commodore Master”). The address for the Firm and Commodore Master is: 767 Fifth Avenue, Floor 12, New York, NY 10153.

 

Item 2. (d) Title of Class of Securities

 

Common Stock, par value $0.01 per share (the “Common Stock”)

 

Item 2. (e) CUSIP No.:

 

92790C104

 

Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person filing is a:

 

N/A

 

 

 

 

CUSIP No. 92790C104 SCHEDULE 13G Page 5 of 7

 

Item 4. Ownership

 

As reported in the cover pages to this report, the ownership information with respect to the Firm is as follows:

 

(a) Amount Beneficially Owned: 1,371,339*

(b) Percent of Class: 5.0%*

(c) Number of Shares as to which such person has:

 

(i) Sole power to vote or to direct the vote: 0

(ii) Shared power to vote or to direct the vote: 1,371,339*

(iii) Sole power to dispose or to direct the disposition of: 0

(iv) Shared power to dispose or to direct the disposition of: 1,371,339*

 

As reported in the cover pages to this report, the ownership information with respect to Commodore Master is as follows:

 

(a) Amount Beneficially Owned: 1,371,339*

(b) Percent of Class: 5.0%*

(c) Number of Shares as to which such person has:

 

(i) Sole power to vote or to direct the vote: 0

(ii) Shared power to vote or to direct the vote: 1,371,339*

(iii) Sole power to dispose or to direct the disposition of: 0

(iv) Shared power to dispose or to direct the disposition of: 1,371,339*

 

*The Firm is the investment manager to Commodore Master. As of May 9, 2022, the Firm may be deemed to beneficially own an aggregate of 1,371,339 shares of Common Stock of the Issuer. The Firm, as the investment manager to Commodore Master, may be deemed to beneficially own these securities. Michael Kramarz and Robert Egen Atkinson are the managing partners of the Firm and exercise investment discretion with respect to these securities. Ownership percentages are based on 27,169,422 shares of Common Stock reported as issued and outstanding in the Issuer’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 27, 2022.

 

Item 5. Ownership of Five Percent or Less of a Class

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

 

Item 6. Ownership of More Than Five Percent on Behalf of Another Person

 

Not Applicable.

 

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

 

Not Applicable.

 

Item 8. Identification and Classification of Members of the Group

 

Not Applicable.

 

Item 9. Notice of Dissolution of Group

 

Not Applicable.

 

Item 10. Certification

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 

 

CUSIP No. 92790C104 SCHEDULE 13G Page 7 of 7

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: May 19, 2022  
   
Commodore Capital LP  
   
By: /s/ Michael Kramarz  
  Michael Kramarz, Managing Partner  
   
Commodore Capital Master LP  
   
By: /s/ Michael Kramarz  
  Michael Kramarz, Authorized Signatory  

 

 

 

 

Exhibit 1

 

JOINT FILING AGREEMENT

 

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that it knows or has reason to believe that such information is inaccurate.

 

 

Dated: May 19, 2022  
   
Commodore Capital LP  
   
By: /s/ Michael Kramarz  
  Michael Kramarz, Managing Partner  
   
Commodore Capital Master LP  
   
By: /s/ Michael Kramarz  
  Michael Kramarz, Authorized Signatory